Vraylar is not an MAOI. It is an atypical antipsychotic, a completely different class of medication that works through a distinct mechanism. The two drug categories affect brain chemistry in fundamentally different ways, and understanding the difference matters if you’re comparing treatment options or concerned about drug interactions.
How Vraylar Is Classified
Vraylar (cariprazine) is classified by the FDA as an atypical antipsychotic. It is approved for four uses in adults: treating schizophrenia, treating manic or mixed episodes in bipolar I disorder, treating depressive episodes in bipolar I disorder, and as an add-on therapy to antidepressants for major depressive disorder.
MAOIs, by contrast, are a class of antidepressants that includes older medications like phenelzine, tranylcypromine, and isocarboxazid. They work by blocking an enzyme called monoamine oxidase, which normally breaks down mood-related brain chemicals like serotonin, norepinephrine, and dopamine. By disabling that enzyme, MAOIs cause those chemicals to build up.
How Vraylar Actually Works
Vraylar takes a very different approach. Rather than blocking an enzyme, it binds directly to specific receptors in the brain, particularly dopamine D3 and D2 receptors, plus certain serotonin receptors. Its strongest attraction is to D3 receptors, where it has a binding affinity roughly six times greater than at D2 receptors.
What makes Vraylar unusual among antipsychotics is that it acts as a partial agonist at these dopamine receptors. This means it can dial dopamine signaling up or down depending on what’s happening in the brain. When dopamine activity is already high (as in mania or psychosis), cariprazine dampens it. When dopamine activity is low (as in depression or the negative symptoms of schizophrenia), it provides a modest boost. It also partially activates serotonin 5-HT1A receptors and blocks 5-HT2B receptors, which likely contributes to its effects on mood.
None of this involves monoamine oxidase. Vraylar does not inhibit any enzymes involved in breaking down neurotransmitters.
Can You Take Vraylar With an MAOI?
While Vraylar is not an MAOI, taking the two together does carry some risk. The interaction is rated as moderate. Combining them can cause additive drops in blood pressure and increased drowsiness or sedation. This applies to all the major MAOIs, including isocarboxazid, phenelzine, and tranylcypromine.
One practical detail worth knowing: Vraylar has an unusually long effective half-life because its active byproducts linger in your body for weeks after you stop taking it. This means potential interactions with other medications can persist well beyond your last dose, which is relevant if you’re switching between Vraylar and an MAOI or any other drug with interaction concerns.
Why People Confuse the Two
The confusion likely comes from the fact that both Vraylar and MAOIs affect the same brain chemicals, particularly dopamine and serotonin. They also overlap in one treatment area: depression. Vraylar is approved as an add-on for major depressive disorder, and MAOIs are antidepressants. But the similarity ends there. They belong to entirely separate drug classes, work through completely different mechanisms, and carry different side effect profiles and dietary restrictions (MAOIs famously require avoiding tyramine-rich foods like aged cheese and cured meats; Vraylar does not).
If you’ve been prescribed Vraylar and were wondering whether it comes with the same precautions as an MAOI, it does not. The two medications are unrelated in how they function, how they’re used, and what you need to watch out for while taking them.